PHARMACEUTICAL COMPOSITION CONTAINING 1,2-DITHIOLTHIONE DERIVATIVE FOR PREVENTING OR TREATING DISEASE CAUSED BY OVEREXPRESSION OF LXR-ALPHA

WIPO Patent Application WO/2010/016681

A3

Provided is a pharmaceutical composition that contains a 1,2-dithiolthionederivative, and is effective to prevent and treat a disease caused by overactivity of a liver X receptor α (LXR α ) or a sterol response element binding protein (SREBP-1). Specifically, the pharmaceutical composition includes 1,2-dithiolthione derivatives such as 4-methyl-5-(2-pyrazinyl)-1,2-dithiol-3-thione, 3-methyl-1,2-dithiol-3-thione, or 5-(6-methoxypyrazinyl)-4-methyl-1,2-dithiol-3-thione. The pharmaceutical composition is effective for preventing and treating hypertension caused by renin, aldosteronism, adrenoleukodystrophy, glomerulosclerosis, proteinuria, nephropathy, liver steatosis, hypertriglyceridemia or hyperreninemia.

KIM SANG GEON (KR)
KI SUNG HWAN (KR)
HWANG SEONG HWAN (KR)

PCT/KR2009/004242

June 03, 2010

July 30, 2009

Click for automatic bibliography generation  

SNU R&DB FOUNDATION (KR)
KIM SANG GEON (KR)
KI SUNG HWAN (KR)
HWANG SEONG HWAN (KR)

A61K31/385

WO2005051941A1	2005-06-09
WO2003020711A1	2003-03-13

JPH07112978A

1995-05-02

VINCENZO O. PALMIERI ET AL.: "Synstemic Oxidative Alterations are Associated with Visceral Adiposity and Liver Steatosis in Patients with Metabolic Syndrome.", THE JOURNAL OF NUTRITION., vol. 136, no. 12, December 2006 (2006-12-01), pages 3022 - 3026, XP008141855
See also references of EP 2307006A4

Y.P. LEE, MOCK & PARTNERS (Seocho-gu, Seoul 137-875, KR)

View/Download PDF      PDF Help

Previous Patent: METHOD OF REPORTING CHANNEL QUALITY INFORMATION IN A WIRELESS COMMUNICATION SYSTEM

Next Patent: METAL PIPE FORMING APPARATUS